Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Propanc Biopharma Inc (PPCB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 2,616
  • Shares Outstanding, K 21,180
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,870 K
  • 36-Month Beta 7.80
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.36
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/27/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1200 +4.17%
on 02/21/18
0.1800 -30.56%
on 01/24/18
-0.0300 (-19.35%)
since 01/19/18
3-Month
0.0900 +38.89%
on 11/28/17
0.7700 -83.77%
on 12/08/17
+0.0300 (+31.58%)
since 11/21/17
52-Week
0.0900 +38.89%
on 11/28/17
3.2500 -96.15%
on 02/23/17
-2.9250 (-95.90%)
since 02/21/17

Most Recent Stories

More News
Propanc Biopharma Receives Allowance of Key Patent Application in the EU

MELBOURNE, Australia , Feb. 20, 2018 /PRNewswire/ --  Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or the "Company"), a clinical stage biopharmaceutical company focusing on development...

PPCB : 0.1250 (+1.21%)
How CEO's of Biotech are Incentivized and What This Means for Investors

FN Media Group Presents Microcapspeculators.com News Commentary

ESPR : 75.83 (+0.05%)
PPCB : 0.1250 (+1.21%)
KURA : 22.50 (+1.35%)
JUNO : 86.64 (+1.95%)
VSTM : 3.18 (-3.05%)
Propanc Biopharma Provides Shareholder Update and Goals for 2018

Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering...

PPCHD : 1.2000 (+20.00%)
PPCB : 0.1250 (+1.21%)
Propanc Biopharma Provides Shareholder Update and Goals for 2018

MELBOURNE, Australia , Feb. 12, 2018 /PRNewswire/ --  Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development...

PPCB : 0.1250 (+1.21%)
Propanc Biopharma Engages Alan Morell of Creative Management Partners as Senior Strategic Advisor to CEO and Board of Directors

Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering...

PPCHD : 1.2000 (+20.00%)
PPCB : 0.1250 (+1.21%)
Propanc Biopharma Repays Magna Invests Senior Secured Convertible Debentures

Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering...

PPCHD : 1.2000 (+20.00%)
PPCB : 0.1250 (+1.21%)
Propanc Biopharma to Present at the 10th Annual Biotech Showcase(TM) 2018

Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering...

PPCHD : 1.2000 (+20.00%)
PPCB : 0.1250 (+1.21%)
Biotech's Flying Under The Radar

Biotech investors spend a ton of time considering what the cure for cancer could be or the next invention that could eliminate a rare disease. It's difficult to keep track of the advancements and developments...

ESPR : 75.83 (+0.05%)
AEZS : 1.86 (-1.06%)
PPCB : 0.1250 (+1.21%)
GERN : 2.25 (+0.45%)
CPRX : 3.15 (-2.78%)
Propanc Biopharma Advances towards GMP Manufacture of PRP for Human Trials

Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering...

PPCHD : 1.2000 (+20.00%)
PPCB : 0.1250 (+1.21%)
Propanc Biopharma Advances towards GMP Manufacture of PRP for Human Trials

MELBOURNE, Australia , Dec. 4, 2017 /PRNewswire/ --  Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development...

PPCB : 0.1250 (+1.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Key Turning Points

2nd Resistance Point 0.1283
1st Resistance Point 0.1267
Last Price 0.1250
1st Support Level 0.1217
2nd Support Level 0.1183

See More

52-Week High 3.2500
Fibonacci 61.8% 2.0429
Fibonacci 50% 1.6700
Fibonacci 38.2% 1.2971
Last Price 0.1250
52-Week Low 0.0900

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.